恶性胸膜间皮瘤免疫微环境与检查点表达及其与临床病理特征和瘤内异质性的时间相关性
该回顾性研究分析了93例初治恶性胸膜间皮瘤(MPM)样本的肿瘤免疫微环境(TME)及PD-L1表达,并与临床病理特征和总生存相关。结果显示,富含细胞毒性T淋巴细胞的TME与侵袭性病理特征、化疗反应差及生存期短相关;化疗后配对样本中细胞毒性T淋巴细胞及免疫细胞PD-L1表达显著增加。
要点
- 肉瘤样/双相型MPM的CD8+ T淋巴细胞及肿瘤细胞PD-L1表达更高,上皮样型则瘤周CD4+ T及CD20+ B淋巴细胞更高。
- 高CD8+ T、CD68+巨噬细胞及PD-L1表达与坏死、分级、Ki-67等侵袭性病理特征相关。
- 包含CD8+ T、坏死、核分裂及增殖指数的联合评分可区分总生存期(11.3个月 vs 16.4个月,P < 0.003)。
核心结论
- 富含细胞毒性T淋巴细胞的TME与巨噬细胞增多、肿瘤细胞PD-L1高表达及侵袭性病理特征相关,并与化疗反应差和生存期短相关。
- 化疗可能诱导肿瘤免疫原性,表现为细胞毒性T淋巴细胞及免疫细胞PD-L1表达增加,但需更大样本验证。
研究设计与样本
- 回顾性研究,收集来自意大利四家及斯洛文尼亚一家癌症中心的MPM患者诊断性活检样本。
- 对15对化疗前后配对样本进行探索性亚组分析。
主要发现
- 肉瘤样/双相型样本的CD8+ T淋巴细胞及肿瘤细胞PD-L1表达高于上皮样型,上皮样型瘤周CD4+ T及CD20+ B淋巴细胞更高。
- 高CD8+ T、CD68+巨噬细胞及PD-L1表达与坏死、分级、Ki-67等侵袭性病理特征相关。
- 高CD8+ T浸润的MPM患者化疗反应更低,单因素分析生存期更短。
- 联合评分(CD8+ T、坏死、核分裂、增殖指数)高组与低组的中位总生存期分别为11.3个月和16.4个月(P < 0.003)。
- 化疗后配对样本中细胞毒性T淋巴细胞及免疫细胞PD-L1表达显著增加。
临床怎么用
- MPM的TME特征(CD8+ T浸润、PD-L1表达)可辅助识别侵袭性强、化疗反应差的患者。
- 联合评分包含CD8+ T、坏死、核分裂及增殖指数,或可用于预后分层。
- 化疗后免疫微环境变化支持免疫检查点抑制剂与化疗联合的探索。
局限性
- 回顾性研究设计。
- 部分样本肿瘤组织不足无法评估PD-L1。
- 化疗前后配对分析仅15对样本,为探索性亚组。
- 化疗作为免疫原性诱导剂的角色需更大验证集确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumor immune microenvironment (TME) plays a key role in malignant pleural mesothelioma (MPM) pathogenesis and treatment outcome, supporting a role of immune checkpoint inhibitors as anticancer approach. This study retrospectively investigated TME and programmed death ligand 1 (PD-L1) expression in naïve MPM cases and their change under chemotherapy. PATIENTS AND METHODS: Diagnostic biopsies of MPM patients were collected from four Italian and one Slovenian cancer centers. Pathological assessment of necrosis, inflammation, grading, and mitosis was carried out. Ki-67, PD-L1 expression, and tumor infiltrating lymphocytes were detected by immunohistochemistry. When available, the same paired sample after chemotherapy was analyzed. Pathological features and clinical characteristics were correlated to overall survival. RESULTS: TME and PD-L1 expression were assessed in 93 and 65 chemonaive MPM samples, respectively. Twenty-eight samples have not sufficient tumor tissue for PD-L1 expression. Sarcomatoid/biphasic samples were characterized by higher CD8+ T lymphocytes and PD-L1 expression on tumor cells, while epithelioid showed higher peritumoral CD4+ T and CD20+ B lymphocytes. Higher CD8+ T lymphocytes, CD68+ macrophages, and PD-L1 expression were associated with pathological features of aggressiveness (necrosis, grading, Ki-67). MPM cases characterized by higher CD8+ T-infiltrate showed lower response to chemotherapy and worse survival at univariate analysis. Patients stratification according to a combined score including CD8+ T lymphocytes, necrosis, mitosis, and proliferation index showed median overall survival of 11.3 months compared with 16.4 months in cases with high versus low combined score (P < 0.003). Subgroup exploratory analysis of 15 paired samples before and after chemotherapy showed a significant increase in cytotoxic T lymphocytes in MPM samples and PD-L1 expression in immune cells. CONCLUSIONS: TME enriched with cytotoxic T lymphocytes is associated with higher levels of macrophages and PD-L1 expression on tumor cells and with aggressive histopathological features, lower response to chemotherapy and shorter survival. The role of chemotherapy as a tumor immunogenicity inducer should be confirmed in a larger validation set.
引用
- Pasello G, Zago G, Lunardi F, et al. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time. Ann Oncol. 2018. PMID: 29514216. doi:10.1093/annonc/mdy086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。